|Table of Contents|

Analysis of prognostic factors related to microwave ablation therapy for lung tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
466-471
Research Field:
Publishing date:

Info

Title:
Analysis of prognostic factors related to microwave ablation therapy for lung tumors
Author(s):
FENG Dongbin1; SHI Yanlong1; WANG Qiang2; XIANG Zhuo2; BI Jingwang2
1.The Postgraduate Training Base of the 960th Hospital of the PLA Joint Service Support Force of Jinzhou Medical University,Shandong Jinan 250031,China；2.Shandong Second People's Hospital,Shandong Jinan 250299,China.
Keywords:
lung tumor; microwave ablation; progression-free-survival; overall survival
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.03.013
Abstract:
Objective:To analyze the relevant factors affecting the prognosis of patients with lung tumors treated with microwave ablation.Methods:A retrospective analysis was conducted on the overall survival(OS),progression-free-survival(PFS),and related factors of adverse reactions and complications of tumor patients who underwent lung microwave ablation from March 2014 to April 2021 at the People's Liberation Army 960 Hospital and the Second People's Hospital of Shandong Province.Results:54 patients were enrolled and a total of 75 lesions were ablated.Single factor and multivariate analysis showed that the tumor location was:2 cm away from the chest wall.Patients who are 2 cm away from the trachea,large blood vessels,and heart have longer PFS and OS(P<0.05).Among the ablation patients,40 cases(74.1%) experienced adverse reactions and complications.The higher the ablation power,the higher the probability of adverse reactions and complications(P<0.05).Adverse reactions and complications were alleviated through corresponding treatment,and no related deaths occurred.Conclusion:Tumor location is an independent prognostic factor for PFS and OS in lung cancer patients treated with microwave ablation,and ablation power is related to the incidence of adverse reactions and complications.

References:

[1]SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA Cancer J Clin,2021,71(1):7-33.
[2]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA Cancer J Clin,2020,70(1):7-30.
[3]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[4]中华人民共和国国家卫生健康委员会.原发性肺癌诊疗指南（2022年版）［J］.中国合理用药探索,2022,19(09):1-28. National Health Commission of the people's Republic of China.Guidelines for the diagnosis and treatment of primary lung cancer(2022 edition )［J］.Chinese Journal of Rational Drug Use,2022,19(09):1-28.
[5]GUTIONTOV SI,PITRODA SP,WECHSELBAUM RR.Oligometastasis:Past,present,future［J］.Int J Radiat Oncol Biol Phys,2020,108(3):530-538.
[6]LIN M,EIKEN P,BLACKMON S.Image guided thermal ablation in lung cancer treatment ［J］.J Thorac Dis,2020,12(11):7039-7047.
[7]锁瑞洋,王绩钊,李硕,等.微波消融在非小细胞肺癌治疗中的应用进展［J］.现代肿瘤医学,2021,29(13):2375-2380. SUO RY,WANG JZ,LI S,et al.Application progress of microwave ablation in non-small cell lung cancer［J］.Modern Oncology,2021,29(13):2375-2380.
[8]NANCE M,KHAZI Z,KAIFI J,et al.Computerized tomography-guided microwave ablation of patients with stage I non-small cell lung cancers:A single-institution retrospective study［J］.Journal of Clinical Imaging Science,2021,11(11):7.
[9]IEZZI R,CIONI R,BASILE D,et al.Standardizing percutaneous microwave ablation in the treatment of lung tumors:a prospective multicenter trial(MALT study)［J］.Eur Radiol,2021,31(4):2173-2182.
[10]HUY,XUE G,LIANG X,WU J,et al.The safety and feasibility of three-dimensional visualization planning system for CT-guided microwave ablation of stage I NSCLC(diameter ≤2.5 cm):A pilot study［J］.J Cancer Res Ther,2023,19(1):64-70.
[11]TSUKIOKA T,IZUMI N,KOMATSU H,et al.Tumor size and N2 lymph node metastasis are significant risk factors for early recurrence in completely resected centrally located primary lung cancer patients［J］.Anticancer Res,2021,41(4):2165-2169.
[12]PALUSSIERE J,LAGARDE P,AUPERIN A,et al.Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer:results of eight years' experience in 87 patients from two centers［J］.Cardiovasc Intervent Radiol,2015,38(1):160-166.
[13]WANG J,LI B,ZHANG L,et al.Safety and local efficacy of computed tomography-guided microwave ablation for treating early-stage non-small cell lung cancer adjacent to bronchovascular bundles［J］.Eur Radiol,2023,28(1):1-2.
[14]YE X,FAN W,WANG Z,et al.Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors(2022 edition)［J］.J Cancer Res Ther,2022,18(5):1213-1230.
[15]Ablation Expert Committee of the Chinese Society of Clinical Oncology,Expert Group on Tumor Ablationn Therapy of the Chinese Medical Doctors Association，Society of Tumor Ablation Therapy of the Chinese Anti-Cancer Association,et al.Clinical practice guidelines:image-guided thermal ablation of primary and metastatic lung tumors(2021 edition)［J］.Chinese Journal of Internal Medicine,2021,60(12):1088-1105.
[16]NI Y,HUANG G,YANG X,et al.Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers:long-term results［J］.Eur Radiol,2022,32(8):5616-5622.
[17]MENG M,HAN X,LI W,et al.CT-guided microwave ablation in patients with lung metastases from breast cancer［J］.Thorac Cancer,2021,12(24):3380-3386.
[18]DE BAERE T,AUPERIN A,DESCHAMPS F,et al.Radiofrequency ablation is a valid treatment option for lung metastases:experience in 566 patients with 1037 metastases［J］.Ann Oncol,2015,26(5):987-991.
[19]SCHLACHTENBERGER G,HEKMAT K,WAHLERS T,et al.Adjuvant chemotherapy for locally advanced non-small cell lung cancer:still state of the art or an outdated therapy［J］.Transl Lung Cancer Res,2023,12(2):204-206.
[20]GOMEZ DR,BLUMENSCHEIN GR JR,LEE JJ,et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre,randomised,controlled,phase 2 study［J］.Lancet Oncol,2016,17(12):1672-1682.
[21]IYENGAR P,KAVANAGH BD,WARDAK Z,et al.Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer［J］.J Clin Oncol,2014,32(34):3824-3830.
[22]GRIFFIIOEN GH,TOGURI D,DAHELE M,et al.Radical treatment of synchronous oligometastatic non-small cell lung carcinoma(NSCLC):patient outcomes and prognostic factors［J］.Lung Cancer,2013,82(1):95-102.
[23]YU J,LIANG P,YU XL,et al.Local tumour progression after ultrasound-guided microwave ablation of liver malignancies:risk factors analysis of 2529 tumours［J］.Eur Radiol,2015,25(4):1119-1126.
[24]MA S,DING M,LI J,et al.Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma:clinical outcomes and prognostic factors［J］.J Cancer Res Clin Oncol,2017,143(1):131-142.
[25]唐浩桓,周奇,孙飞虎，等.微波消融治疗肺恶性肿瘤安全性及疗效的单中心临床分析［J］.中国胸心血管外科临床杂志,2021,28(11):1310-1314. TANG HH,ZHOU Q,SUN FH,et al.Single center clinical analysis of the safety and efficacy of microwave ablation in the treatment of pulmonary malignant tumors［J］.Chinese Journal of Clinical Thoracic and Cardiovascular Surgery,2021,28(11):1310-1314.

Memo

Memo:
山东省自然科学基金（编号：ZR2022MC028）
Last Update: 2023-12-29